Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome.

Bannister EG, Yuen L, Littlejohn M, Edwards R, Sozzi V, Colledge D, Li X, Locarnini S, Hardikar W, Revill PA.

J Gen Virol. 2018 Aug;99(8):1103-1114. doi: 10.1099/jgv.0.001086. Epub 2018 Jun 22.

PMID:
29932395
2.

In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease.

Sozzi V, Shen F, Chen J, Colledge D, Jackson K, Locarnini S, Yuan Z, Revill PA.

Virology. 2018 Jun;519:190-196. doi: 10.1016/j.virol.2018.04.015. Epub 2018 May 4.

PMID:
29734042
3.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro.

Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, Michienzi A, Andreoni M, Francioso S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, Svicher V.

Oncotarget. 2017 Feb 28;8(9):15704-15715. doi: 10.18632/oncotarget.14944.

4.

Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis.

Colledge D, Soppe S, Yuen L, Selleck L, Walsh R, Locarnini S, Warner N.

Virology. 2017 Jan 15;501:70-78. doi: 10.1016/j.virol.2016.11.007. Epub 2016 Nov 19.

5.

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes.

Sozzi V, Walsh R, Littlejohn M, Colledge D, Jackson K, Warner N, Yuen L, Locarnini SA, Revill PA.

J Virol. 2016 Oct 28;90(22):10054-10064. Print 2016 Nov 15.

6.

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.

Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA.

Gut. 2017 Nov;66(11):2013-2023. doi: 10.1136/gutjnl-2015-309300. Epub 2016 Aug 17.

PMID:
27534671
7.

Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation.

Betz-Stablein BD, Töpfer A, Littlejohn M, Yuen L, Colledge D, Sozzi V, Angus P, Thompson A, Revill P, Beerenwinkel N, Warner N, Luciani F.

J Virol. 2016 Jul 27;90(16):7171-7183. doi: 10.1128/JVI.00243-16. Print 2016 Aug 15.

8.

Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.

Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA.

J Viral Hepat. 2016 Mar;23(3):170-9. doi: 10.1111/jvh.12477. Epub 2015 Oct 5.

PMID:
26436722
9.

Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.

Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD, Ojaimi S, Scott HW, Baschuk N, Nachbur U, Torresi J, Chin R, Colledge D, Li X, Warner N, Revill P, Bowden S, Silke J, Begley CG, Pellegrini M.

Proc Natl Acad Sci U S A. 2015 May 5;112(18):5797-802. doi: 10.1073/pnas.1502390112. Epub 2015 Apr 20.

10.

A novel hepatitis B virus S gene insertion associated with reduced humoral immunity and diagnostic escape.

Flanagan E, Thompson AJ, Colledge D, Edwards R, Littlejohn M, Walsh R, Warner N, Bowden DS, Iser DM.

Intern Med J. 2014 Jul;44(7):709-10. doi: 10.1111/imj.12465. No abstract available.

PMID:
25041776
11.

Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen.

Jegaskanda S, Ahn SH, Skinner N, Thompson AJ, Ngyuen T, Holmes J, De Rose R, Navis M, Winnall WR, Kramski M, Bernardi G, Bayliss J, Colledge D, Sozzi V, Visvanathan K, Locarnini SA, Kent SJ, Revill PA.

J Virol. 2014 Sep;88(18):10412-20. doi: 10.1128/JVI.00111-14. Epub 2014 May 28.

12.

Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype.

Li W, Warner N, Sozzi V, Yuen L, Colledge D, Li T, Zhuang H, Locarnini S, Revill PA.

Hepatol Int. 2013 Jun;7(2):443-50. doi: 10.1007/s12072-012-9411-2. Epub 2012 Nov 28.

PMID:
26201776
13.

In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection.

Cabuang LM, Shaw T, Littlejohn M, Colledge D, Sozzi V, Soppe S, Warner N, Thompson A, Preiss S, Lam N, Walsh R, Lewin SR, Thio CL, Matthews G, Locarnini SA, Revill PA.

J Med Virol. 2012 Aug;84(8):1166-76. doi: 10.1002/jmv.23328.

14.

The hepatitis B e antigen suppresses IL-1β-mediated NF-κB activation in hepatocytes.

Wilson R, Warner N, Ryan K, Selleck L, Colledge D, Rodgers S, Li K, Revill P, Locarnini S.

J Viral Hepat. 2011 Oct;18(10):e499-507. doi: 10.1111/j.1365-2893.2011.01484.x. Epub 2011 Aug 18.

PMID:
21914069
15.

Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody.

Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, Dolezal O, Griffiths K, Bartholomeusz A, Locarnini S.

Virology. 2011 Mar 1;411(1):132-41. doi: 10.1016/j.virol.2010.12.034. Epub 2011 Jan 15.

16.

Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro.

Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S.

Antivir Ther. 2009;14(6):797-808. doi: 10.3851/IMP1294.

PMID:
19812442
17.

The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.

Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA.

Antiviral Res. 2007 Nov;76(2):168-77. Epub 2007 Jul 24.

PMID:
17709147
18.

Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.

Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA.

AIDS. 2007 Aug 20;21(13):1701-10.

PMID:
17690567
19.

SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, Locarnini SA, Bartholomeusz A.

Antiviral Res. 2007 Jul;75(1):64-74. Epub 2006 Dec 22.

PMID:
17215050
20.

Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells.

Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K, Lemon SM, Lau GG, Beard MR.

J Clin Virol. 2005 Feb;32(2):113-21.

PMID:
15653413
21.

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S.

Gastroenterology. 2003 Aug;125(2):292-7.

PMID:
12891527
22.

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.

Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE 4th, Isom H, Bowden S, Desmond P, Locarnini SA.

Hepatology. 2003 Jan;37(1):27-35.

PMID:
12500185
23.

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.

Delaney WE 4th, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S.

Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60.

24.

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Delaney WE 4th, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini S.

Antimicrob Agents Chemother. 2001 Jun;45(6):1705-13.

25.

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Colledge D, Civitico G, Locarnini S, Shaw T.

Antimicrob Agents Chemother. 2000 Mar;44(3):551-60.

26.

Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1- yl)purines as potential prodrugs of penciclovir.

Kim DK, Lee N, Ryu DH, Kim YW, Kim JS, Chang K, Im GJ, Choi WS, Cho YB, Kim KH, Colledge D, Locarnini S.

Bioorg Med Chem. 1999 Aug;7(8):1715-25.

PMID:
10482463
27.

Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA.

Antimicrob Agents Chemother. 1998 Dec;42(12):3130-5.

28.

Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S.

Antimicrob Agents Chemother. 1998 Aug;42(8):2132-7.

29.
30.

Computer-based surgical audit programs: a review of three current options.

Colledge DN, White S.

Aust N Z J Surg. 1997 Apr;67(4):206-10.

PMID:
9137162
31.

Linking home and residential school.

Colledge D, Wood C.

Spec Educ Forward Trends. 1982 Mar;9(1):17-8. No abstract available.

PMID:
6461075

Supplemental Content

Loading ...
Support Center